Table 1.
Clinical data from the 24 CTCL patients with blood involvement
| Patient sample | Gender | Age | Status at 1 year | Initial skin stage/BSA | Skin score at 1 year | Treatment at sample collection | Evidence for blood involvement | CD4/ CD8 ratio | Population isolated | Gene expression data | SNP data |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Male | 84 | Stable | T4; >50% | Improved | ECP | PCR for TCR-β/γ (+), CD45RO elevated | 1.7 | CD4+ | — | Yes |
| 2 | Female | 85 | Stable | T4; >50% | Improved | ECP, Targretin | PCR for TCR-β/γ (+), CD45RO elevated, CD4+CD7− elevated, CD4+CD26− elevated | 1.6 | CD4+CD7−CD26− | — | Yes |
| 3 | Male | 86 | Stable | T4; >50% | Improved | ECP, Targretin | PCR for TCR-β/γ (+), Vα | 2.9 | CD4+ | Yes | Yes |
| 4 | Female | 50 | Stable | T2; >10% | Improved | ECP, IFN-α | PCR for TCR-β/γ (+) | 38 | CD4+CD7− | Yes | Yes |
| 5 | Male | 66 | Deceased | T4; >50% | Nonresponsive | ECP | PCR for TCR-β/γ (+), CD45RO elevated, CD4+CD7− elevated, CD4+CD26− elevated | 99 | CD4+CD7−CD26− | Yes | Yes |
| 6 | Male | 52 | Improved | T3; >50% | Improved | ECP, Targretin | ? | 2.3 | CD4+ | — | Yes |
| 7 | Female | 76 | Improved | T3; <10% | Improved | ECP | PCR for TCR-β/γ (+) | 0.79 | CD4+ | Yes | Yes |
| 8 | Female | 83 | Improved | T2; 10–50% | Improved | ECP | PCR for TCR-β/γ (+), Vβ8a | 0.28 | CD4+ | — | Yes |
| 9 | Male | 53 | Stable | T4; 100% | Nonresponsive | ECP | PCR for TCR-β/γ (+), CD45RO elevated | 1.2 | CD4+ | Yes | — |
| 10 | Female | 86 | Worsened | T2; 10–50% | Worsened | ECP, Ontak | PCR for TCR-β/γ (+), CD4+CD26− elevated, Vβ2 | 19.7 | CD4+CD26− | Yes | Yes |
| 11 | Female | 72 | Worsened | T4; >50% | Nonresponsive | ECP, Targretin, IFN-α | PCR for TCR-β/γ (+), CD45RO elevated, CD4+CD7− elevated, CD4+CD26− elevated | 3.5 | CD4+CD7−CD26− | Yes | Yes |
| 12 | Male | 62 | Improved | T4; >50% | Improved | ECP, Targretin | PCR for TCR-β/γ (+), CD45RO elevated, CD4+CD7− elevated, CD4+CD26− elevated, previous Vβ5a | 2.8 | CD4+CD7−CD26− | Yes | Yes |
| 13 | Male | 31 | Improved | T4; >50% | Improved | ECP | PCR for TCR-β/γ (+), previous Vα12.1 | 1.6 | CD4+ | — | Yes |
| 14 | Male | 76 | Stable | T2; 10–50% | Worsened | ECP | PCR for TCR-β/γ (+), CD45RO elevated, CD4+CD26− elevated | 18.5 | CD4+CD26− | — | Yes |
| 15 | Female | 56 | Improved | T4; >50% | Improved | ECP | PCR for TCR-β/γ (+), CD45RO elevated, Vβ5a | 1.4 | CD4+ | — | Yes |
| 16 | Male | 84 | Worsened | T4; >50% | Worsened | ECP, Targretin | PCR for TCR-β/γ (+), CD45RO elevated, CD4+CD7− elevated, CD4+CD26− elevated, Vβ5a | 4.9 | CD4+CD7−CD26− | — | Yes |
| 17 | Female | 80 | Improved | T4; >50% | Improved | ECP | PCR for TCR-β/γ (−), previous CD4/CD8 ratio of 11.6 | 3.3 | CD4+ | Yes | Yes |
| 18 | Female | 88 | Deceased | T4; >50% | Improved | ECP, Targretin | PCR for TCR-β/γ (+), CD45RO elevated, CD4+CD26− elevated, Vβ5c | 3.6 | CD4+CD26− | Yes | Yes |
| 19 | Male | 54 | Stable | T4; >50% | Improved | ECP, Targretin, IFN-α | PCR for TCR-β/γ (+) | 3.1 | CD4+ | Yes | Yes |
| 20 | Male | 65 | Stable | T4; >50% | Improved | ECP, Targretin | PCR for TCR-β/γ (+), CD45RO elevated, CD4+CD7− elevated, CD4+, CD26− elevated, Vβ3 | 3.4 | CD4+CD7−CD26− | Yes | Yes |
| 21 | Male | 75 | Deceased | T4; >50% | Nonresponsive | ECP, MTX, IFNα | PCR for TCR-β/γ (+), CD45RO elevated, CD4+CD7− elevated, CD4+CD26− elevated | 7.5 | CD4+CD7−CD26− | — | Yes |
| 22 | Male | 63 | Deceased | T4; >50% | Improved | ECP | PCR for TCR-β/γ (−), Vβ5a | 7.6 | CD4+ | — | Yes |
| 24 | Male | 45 | Improved | T2; 10–50% | Improved | ECP, Targretin, IFN-α | PCR for TCR-β/γ (−), previous Vα12.1 | 3.1 | CD4+ | — | Yes |
| 25 | Female | 37 | No data | T4; >50% | Nonresponsive | ECP | PCR for TCR-β/γ (−), previous Vβ20 | 1.2 | CD4+ | — | Yes |
Abbreviations: BSA, body surface area; CTCL, cutaneous T-cell lymphoma; ECP, extracorporeal photopheresis; MTX, methotrexate; SNP, single-nucleotide polymorphism.
Please see Materials and Methods for information regarding collection of data.